5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and consumes the methyl-donor S-adenosylmethionine (SAM) in the process. NNMT activity is upregulated in adipose tissue with ageing and obesity, where it depletes both the NAD+ precursor pool (via nicotinamide consumption) and the cellular methylation capacity (via SAM consumption). 5-Amino-1MQ research focuses on the metabolic and adipose-tissue effects of restoring NAD+ availability and methylation balance through NNMT blockade — distinct from but complementary to the direct NAD+ restoration strategies (NMN, NR, direct NAD+ administration).
NNMT (nicotinamide N-methyltransferase) catalyses the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), using S-adenosylmethionine (SAM) as the methyl donor and producing S-adenosylhomocysteine (SAH) as a byproduct. The substrate consumption matters in two ways: nicotinamide is the precursor for the NAD+ salvage pathway (so NNMT activity diverts substrate away from NAD+ regeneration), and SAM is the universal methyl donor (so NNMT activity competes with epigenetic, neurotransmitter and protein methylation reactions).
NNMT expression is markedly upregulated in adipose tissue with ageing and obesity. The Banks/Imai work and follow-on research has established NNMT as a metabolic checkpoint enzyme whose activity contributes to the age- and obesity-associated decline in tissue NAD+ levels and methylation capacity.
5-Amino-1MQ is a small-molecule NNMT inhibitor (Neelakantan et al.) that competitively blocks the NNMT active site. Preclinical research in obesity models has documented reduced fat mass and improved metabolic markers with 5-Amino-1MQ dosing — effects attributed to restored adipose NAD+ levels and methylation capacity rather than direct lipolytic or anorexigenic activity.
Foundational research from Banks, Imai and colleagues (Cell Metabolism, 2014; Nature Communications, 2018) established NNMT as a metabolic checkpoint in adipose tissue. NNMT knockout mice on high-fat diet were protected from diet-induced obesity; NNMT expression in adipose biopsies correlated with insulin resistance in human cohorts.
5-Amino-1MQ research has built directly on this. Preclinical obesity models with 5-Amino-1MQ dosing have documented reduced fat mass, improved glucose tolerance and preserved metabolic flexibility — outcomes attributed to the restored NAD+/methylation balance in adipocytes rather than direct anorexigenic effects.
5-Amino-1MQ occupies a distinct position in NAD+-restoration research. Where direct NAD+ administration and the precursor strategies (NMN, NR) increase the substrate pool from outside, NNMT inhibition prevents internal substrate depletion — a "spare the precursor" rather than "supplement the precursor" pharmacologic strategy.
The compound is included in the Mito Stack alongside NAD+ and MOTS-c, where the three components address three distinct nodes of the NAD+/mitochondrial energy axis: direct substrate provision (NAD+), upstream signalling (MOTS-c on AMPK), and the NNMT bottleneck (5-Amino-1MQ).